GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Current Ratio

Clover Biopharmaceuticals (HKSE:02197) Current Ratio : 0.83 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Clover Biopharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 0.83.

Clover Biopharmaceuticals has a current ratio of 0.83. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Clover Biopharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Clover Biopharmaceuticals's Current Ratio or its related term are showing as below:

HKSE:02197' s Current Ratio Range Over the Past 10 Years
Min: 0.83   Med: 2.36   Max: 15.71
Current: 0.83

During the past 5 years, Clover Biopharmaceuticals's highest Current Ratio was 15.71. The lowest was 0.83. And the median was 2.36.

HKSE:02197's Current Ratio is ranked worse than
85.1% of 1544 companies
in the Biotechnology industry
Industry Median: 3.775 vs HKSE:02197: 0.83

Clover Biopharmaceuticals Current Ratio Historical Data

The historical data trend for Clover Biopharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Current Ratio Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
5.98 15.71 2.36 1.55 0.83

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial 2.36 1.88 1.55 1.19 0.83

Competitive Comparison of Clover Biopharmaceuticals's Current Ratio

For the Biotechnology subindustry, Clover Biopharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Biopharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Current Ratio falls into.



Clover Biopharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Clover Biopharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=2077.654/2490.538
=0.83

Clover Biopharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2077.654/2490.538
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clover Biopharmaceuticals  (HKSE:02197) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Clover Biopharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals (HKSE:02197) Business Description

Traded in Other Exchanges
N/A
Address
1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines